SCHEMBL21842091

SCHEMBL21842091

CCCOC(=O)c1ccc(OC2CCN(C)C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 3/20 0.52
SCN2A Q99250 3/20 0.52
SCN3A Q9NY46 3/20 0.52
TSHR P16473 3/20 0.49
ESR1 P03372 2/20 0.49
ALDH1A1 P00352 1/20 0.49
CHRM1 P11229 1/20 0.49
SLC6A2 P23975 1/20 0.49
KDR P35968 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
STS P08842 1/20 0.48
LMNA P02545 3/20 0.47
CHEK2 O96017 1/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
PDE4D Q08499 1/20 0.46
UTS2R Q9UKP6 1/20 0.45
ACACB O00763 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17869387 0.90 SCN1A (0.51) SCN1ASCN2ASCN3AESR1LMNA
SCHEMBL24244964 0.84 L3MBTL1 (0.54) SCN1ASCN2ASCN3AALDH1A1LMNA
SCHEMBL24244916 0.83 SCN1A (0.56) SCN1ASCN2ASCN3ALMNACYP1A2
SCHEMBL22664150 0.82 SCN1A (0.51) SCN1ASCN2ASCN3ACHEK2UTS2R
SCHEMBL20179660 0.82 SCN1A (0.51) SCN1ASCN2ASCN3ACHEK2UTS2R
SCHEMBL22664149 0.79 ALDH1A1 (0.55) ALDH1A1CHRM1TDP1LMNACHEK2
SCHEMBL17869370 0.79 ALDH1A1 (0.55) ALDH1A1CHRM1TDP1LMNACHEK2
SCHEMBL17072674 0.76 HRH3 (0.50) UTS2RACACBKMT2ASMN1; SMN2MEN1
SCHEMBL3458256 0.75 SCN1A (0.56) SCN1ASCN2ASCN3ALMNACHEK2
SCHEMBL14487845 0.75 CHRNB2 (0.54) SCN1ASCN2ASCN3AALDH1A1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3623372-A1 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Forma Therapeutics, Inc. (US) 2020-03-18 EP disclosed